FOR IMMEDIATE RELEASE Media Contact: Caralynn Nowinski Collens, CEO, Dimension Inx, caralynncollens@dimensioninx.com

Dimension Inx Announces Issuance of U.S. Patent for Biomaterials Design and 3D-Printing Manufacturing System.

Biofabrication company expands its patent portfolio with seminal patent protecting its “3D-Painting System” and proprietary bioinks for organ and tissue repair and regeneration

CHICAGO, Illinois, USA – March 10, 2020– Dimension Inx, a biofabrication company developing regenerative medical products, announces the issuance of a seminal patent covering the game-changing “3D-Painting System” employed by the company to design and manufacture next-generation biomaterials for organ and tissue repair and regeneration.

The proprietary 3D-Painting System allows for high loading of bioactive ingredients, rapid printing and drying at room temperature, and the elimination of processing techniques like cross-linking and sintering. These features are critical for conferring the necessary composition and microstructure of surgical implants that promote healing and tissue regeneration. The speed of manufacturing also facilitates the commercial scaling of novel medical products.

“As we move toward the clinic with our first medical products, this patent strengthens the differentiation and defensibility of our biomaterials platform,” said Caralynn Nowinski Collens, M.D., Chief Executive Officer. “Further, it advances our mission of delivering regenerative medical products to the patients that need them by being the industry partner of choice for biomaterials design and production.”

Dimension Inx has exclusive worldwide rights to commercialize these inventions as part of a broad intellectual property portfolio licensed from Northwestern University. Inventors and company cofounders, Ramille Shah, Ph.D., and Adam Jakus, Ph.D., developed this portfolio from nearly a decade of research at Northwestern’s Tissue Engineering and Additive Manufacturing Lab. Dr. Shah, director of the lab and now Dimension Inx’s Chief Scientific Officer, was also recognized last week by the American Society of Mechanical Engineers (ASME) as one of “10 Influential Women in Engineering”.

U.S. Patent No. 10,584,254, “A Universal Method for Production and 3D-Printing of High-ParticleContent 3D-Inks”, is directed to compositions, materials, and methods for production and 3D-Printing of high-particle-content 3D-inks. The newly issued patent is part of a family of patents previously granted in Japan (P6542807) and Australia (AU2015258978).

“The award of this patent recognizes the novelty and value of the 3D-Painting System,” remarks Dr. Jakus, the company’s Chief Technology Officer. “The innovation protected here overcomes hurdles faced by other 3D-printing and bioprinting methods and enables, for the first time, the ability to create and rapidly 3D-print an extensive range of biomaterials without heat or other processing techniques that limit or destroy bioactivity.”

+ About Dimension Inx

Dimension Inx is a biofabrication company harnessing the power of a patented 3D-printing biomaterials design and manufacturing platform to create regenerative medical products that fundamentally change how we treat human disease and debilitation. The company is developing a new class of treatments that dramatically improves the standard of care and addresses the shortage of donor tissues and organs. The Dimension Inx team brings expertise in materials science and tissue engineering to partner with the world’s best clinicians and surgeons and leading medical products companies to deliver new medical solutions to patients.

Dimension Inx is proudly based in Chicago, Illinois.  To learn more about our team and our technology, please visit www.dimensioninx.com.